Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

Launched by TRIHEALTH INC. · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how a supplement called Nicotinamide Mononucleotide (NMN) might help improve the immune system in people living with HIV who are on treatment but still have low levels of a specific type of immune cell called CD4+ T cells. These cells are important for fighting infections, and the study will see if taking NMN daily for 12 weeks can help increase their numbers and improve overall immune health. The trial will track changes in CD4+ T cell counts, safety of the supplement, and participants' quality of life.

To participate, you must be an adult aged 18 or older with well-controlled HIV, meaning you have had two negative viral load tests in the past six months and a low CD4+ T cell count for at least two years. The study involves two in-person visits and some phone check-ins, where you'll be asked to log your daily supplement intake and any side effects. This trial is not yet recruiting participants, so if you're interested, keep an eye out for when it opens.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HIV-infected adults aged 18 years or older
• • Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months
• • Confirmed diagnosis of immunological failure (CD4+ T cell count \<350 cells/µL 2 years after effective ART initiation)
• • Willing to provide informed consent
• Exclusion Criteria:
• • Active opportunistic infections
• • Known allergies or sensitivities to NMN or any components of the NMN supplement
• • Current or recent use of other supplements or medications known to affect NAD+ metabolism (Niacin, NR, NMNH, etc.)
• • Pregnancy or breastfeeding
• • Significant liver or kidney disease
• • Active malignancy
• • History of uncontrolled substance abuse
• • Severe medical conditions that might interfere with study participation
• • Unable to consent